-+ 0.00%
-+ 0.00%
-+ 0.00%

SynAct Pharma Set to Obtain US Patent for Resomelagon Tablets

MT Newswires·11/13/2026 04:58:20
Listen to the news
04:58 AM EST, 11/13/2026 (MT Newswires) -- SynAct Pharma (SYNACT.ST) received a notice of allowance from the US Patent and Trademark Office for a patent covering an immediate-release solid oral dosage formulation of resomelagon in clinical testing. The patent for resomelagon tablet is expected to be granted within a few weeks, according to a Friday release. The biotechnology company already has two US patents covering the crystal form of resomelagon, an oral selective melanocortin agonist to treat rheumatoid arthritis and certain viral infections.